Form 4 for MBX MBX Biosciences, Inc.
Accepted 2026-05-11 16:01:35 ET · period of report 2026-05-08 · accession 0001193125-26-216704 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-11 16:01 | 2026-05-08 | MBX | Azoulay Salomon | Chief Medical Off | M - OptEx | $11.65 | +70.0K | 29.8K | New | +$815.3K |
| DMT | 2026-05-11 16:01 | 2026-05-08 | MBX | Azoulay Salomon | Chief Medical Off | S - Sale+OE | $38.36 | -70.0K | 14.8K | -83% | -$2.69M |
| DMT | 2026-05-11 16:01 | 2026-05-08 | MBX | Azoulay Salomon | Chief Medical Off | M - OptEx | $0.00 | +70.0K | 30.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-08 | M | A | 55,000 | $10.46 | 69,769 | D | — | — | (F1) The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. |
| 2 | Common | Common Stock | 2026-05-08 | S | D | 55,000 | $38.38 | 14,769 | D | — | — | (F1) The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-05-08 | M | A | 15,003 | $16.00 | 29,772 | D | — | — | (F1) The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. |
| 4 | Common | Common Stock | 2026-05-08 | S | D | 15,003 | $38.30 | 14,769 | D | — | — | (F1) The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Stock option (right to buy) | 2026-05-08 | M | A | 55,000 | $0.00 | 194,540 | D | $10.46 · — to 2034-08-02 | 55,000 Common Stock | (F4) 25% of the shares underlying this option vested and became exercisable on June 24, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| 6 | Derivative | Stock option (right to buy) | 2026-05-08 | M | A | 15,003 | $0.00 | 30,008 | D | $16.00 · — to 2034-09-12 | 15,003 Common Stock | (F5) 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |